Fosun Pharma: Majority-owned subsidiary drug receives approval for clinical trials.

Fosun Pharma announced that its holding subsidiary Shanghai Fosun Hanlin Bio-Tech Co., Ltd. and its holding subsidiary have received approval from the National Medical Products Administration to conduct Phase I clinical trials of injection HLX316 for the treatment of advanced/metastatic solid tumors.